But giving money to disease-specific charities is still a bad idea.
Meta
Categories
- accounting
- Announcements
- architecture
- art
- auctions
- bailouts
- banking
- bankruptcy
- ben stein watch
- blogonomics
- bonds and loans
- charts
- china
- cities
- climate change
- commercial property
- commodities
- consumers
- consumption
- corporatespeak
- credit ratings
- crime
- Culture
- Davos 2008
- Davos 2009
- defenestrations
- demographics
- derivatives
- design
- development
- drugs
- Econoblog
- economics
- education
- emerging markets
- employment
- energy
- entitlements
- eschatology
- euro
- facial hair
- fashion
- Film
- Finance
- fiscal and monetary policy
- food
- foreign exchange
- fraud
- gambling
- geopolitics
- governance
- healthcare
- hedge funds
- holidays
- housing
- humor
- Humour
- iceland
- IMF
- immigration
- infrastructure
- insurance
- intellectual property
- investing
- journalism
- labor
- language
- law
- leadership
- leaks
- M&A
- Media
- milken 2008
- Not economics
- pay
- personal finance
- philanthropy
- pirates
- Politics
- Portfolio
- prediction markets
- private banking
- private equity
- privatization
- productivity
- publishing
- race
- rants
- regulation
- remainders
- research
- Restaurants
- Rhian in Antarctica
- risk
- satire
- science
- shareholder activism
- sovereign debt
- sports
- statistics
- stocks
- taxes
- technocrats
- technology
- trade
- travel
- Uncategorized
- water
- wealth
- world bank
Archives
- March 2023
- August 2022
- July 2022
- June 2022
- May 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- December 2012
- August 2012
- June 2012
- March 2012
- April 2011
- August 2010
- June 2010
- January 2010
- December 2009
- September 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- April 2007
- March 2007
- February 2007
- January 2007
- December 2006
- November 2006
- October 2006
- September 2006
- August 2006
- July 2006
- June 2006
- May 2006
- April 2006
- March 2006
- February 2006
- January 2006
- December 2005
- November 2005
- October 2005
- September 2005
- August 2005
- July 2005
- June 2005
- May 2005
- April 2005
- March 2005
- February 2005
- January 2005
- December 2004
- November 2004
- October 2004
- September 2004
- August 2004
- July 2004
- June 2004
- May 2004
- April 2004
- March 2004
- February 2004
- January 2004
- December 2003
- November 2003
- October 2003
- September 2003
- August 2003
- July 2003
- June 2003
- May 2003
- April 2003
- March 2003
- February 2003
- January 2003
- December 2002
- November 2002
- October 2002
- September 2002
- August 2002
- July 2002
- June 2002
- May 2002
- March 2002
- February 2002
- January 2002
- December 2001
- November 2001
- October 2001
- September 2001
- August 2001
- July 2001
- June 2001
- May 2001
- April 2001
- March 2001
- February 2001
- January 2001
- December 2000
- September 2000
- July 2000
- March 2000
- July 1999
just for background, i am a scientist that works on cures like this, mostly for cancer. i have degrees from state schools, i have degrees from ivy league schools. i have received research grants from private, disease-focused foundations, such as the one you are attacking here, as well as the NIH. and i too have lost family and friends to “difficult” diseases that I’m sure you would shun like ALS.
Your article is one of the worst I have seen in quite a while. you have no idea how change happens in medicine and disease and your thought of “why spend money on research now when it is going to take a long time to make a difference” and then say “why don’t people make the world a better place by giving money to homeless people or some other charity that is going to throw money at a problem that will be no different tomorrow” is insanely short sided.
yea, we didn’t have a vaccine for polio, until people spent decades working on it – and then we did, and then we eradicated it, and that had a MASSIVE effect on childhood mortality and morbidity. you can say the same about countless other diseases that we developed vaccines for as well. and we didn’t have drugs to slow down hiv and aids to the point that people live decades instead of months – until advocacy groups mobilized private donations and government organizations – and then we did. for countless cancers, death rates used to be 90%+, but research was done, slow and steady at first, and then usually there is an inflection point, a drug target, a drug candidate – and then everyone applauds the foundations and the people who donated the money to allow the scientists to work on risky things for years, sometimes decades, to get it to that point. then if those discoveries work, and translate, and a new procedure or medicine is born, then everyone is better off for it.however, science is very expensive and there are pressures from granting agencies and departments and universities etc, so you can’t spend millions of dollars a year to work on something risky and new (and all new discoveries that really affect human health are just those things until they have “worked”) without money. you have to pay salaries, buy equipment, pay for reagents etc etc. in the world you, the author of this lovely piece, live in, we shouldn’t put any money into research for diseases like ALS, because, you know, it’s a hard one, and it might take a while, so screw all those people who are going to die a long, terrible death as their body completely gives out on them. instead, go give some money to the local guy on the corner, who was there two years ago and is going to be there for the next two years, that will do a lot of good for everyone. that guy is most likely there because he has mental illness, so maybe donate to research on those disorders, but, oh yea, they are even more complicated than ALS, screw that – just give him some beer money and tell him you’ll see him tomorrow.
Hi Felix.
I read your article with great pleasure. These campaigns are great at self promotion, due to their “selfie nature”. You know Take a selfie, yell name of charity, hold it over your friends as a badge of honour.
But we believe there is a better way. we’re a startup that would like to talk to you our approach to charities. IF you’re interested just e-mail me.
Hi Felix, I read your article about ALS and while you bring up some good points and valid concerns, I think it’s important not to be too quick to condemn. As someone who’s lost a family member to ALS and as a biotech investor, I personally would rather see every dollar raised in the challenge go directly to various biotechs that work on neuro diseases (they are all related, so knowledge and treatments gleaned about one often carries over to others). The millions raised over the past few weeks could probably fund a dozen biotechs through phase 3 trials. One biotech (http://www.neuralstem.com/, I am an investor) has come up what may turn out to be a true treatment or cure, so ALS and hopefully all neuro problems are close to an inflection point. But at the same time, there are people out there with these diseases that are fighting and losing just to do little things like walk, say “I love you”, breathe, and eat. Many of these people won’t be around long enough to receive a treatment that works, and in lieu of that treatment, ALSA can soften the blows greatly for these patients and families, despite bloated administrative expenses etc. And lastly, we don’t yet know what will be done with all that money, I’m sure the ALSA community is feverishly debating it right now. And until these obscure diseases are treatable, maybe it’s not such a terrible thing to throw money at them? Ten years ago when my grandmother was diagnosed, hardly anyone I knew had heard of ALS. Now, hardly anyone doesn’t, and I think that’s a good thing not just for ALS but all neuro diseases.
One point that you do not really address is the NIH funding disparity among research into diseases. There are certain maladies that have a highly disproportionate amount of government and private funding relative to others.
Take, for example, Autism. No one disputes that autism is a terrible affliction. According to NIH, it affects 1 in 88 children age 8. NIH spent $186 million in 2013 on research, and Autism Speaks has spent over $100 million to date.
Contrast this with food allergies. CDC estimates 5% of US children have food allergies and there are dozens to hundreds of deaths each year. So roughly 4 times as many children have food allergies compared to children who have Autism. NIH spending in 2013 on food allergy research was $36 million, or about 1/5th of what was spent on Autism. The largest private food allergy charity, FARE, spent $5 million on research last year. So a disease that affects many more people and kills more children receives far less funding, both public and private.
This shows that the NIH is not always the best arbiter of how public money is spent on research. Politics, celebrity endorsements, and public perception can cloud public budget allocation in health spending, just like other forms of government spending. The private market is the only way to try to get funding to research in many underfunded diseases because the NIH spending model just appears to be broken in some cases.
I would love to hear your thoughts on this, either here or in a future article.